Annuncio pubblicitario
Italia markets open in 43 minutes
  • Dow Jones

    38.085,80
    -375,12 (-0,98%)
     
  • Nasdaq

    15.611,76
    -100,99 (-0,64%)
     
  • Nikkei 225

    37.926,80
    +298,32 (+0,79%)
     
  • EUR/USD

    1,0734
    +0,0001 (+0,01%)
     
  • Bitcoin EUR

    60.088,45
    +176,78 (+0,30%)
     
  • CMC Crypto 200

    1.392,81
    -3,73 (-0,27%)
     
  • HANG SENG

    17.720,97
    +436,43 (+2,53%)
     
  • S&P 500

    5.048,42
    -23,21 (-0,46%)
     

Cara Therapeutics to Present at Upcoming Investor Conferences

Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that members of its Executive Leadership Team will present at the following investor conferences:

Stifel Healthcare Conference
Tuesday, November 15, 2022, at 10:55 a.m. ET

Jefferies London Healthcare Conference
Wednesday, November 16, 2022, at 10 a.m. ET (3 p.m. GMT)

Evercore ISI Healthcare Conference (virtual)
Tuesday, November 29, 2022, at 8:25 a.m. ET

ANNUNCIO PUBBLICITARIO

Piper Sandler Healthcare Conference
Thursday, December 1, 2022, at 8 a.m. ET

Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com